{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:26:46Z","timestamp":1794043606225,"version":"4.8.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eururo.2026.05.030","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:40:54Z","timestamp":1782531654000},"page":"377-388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1486-183X","authenticated-orcid":false,"given":"Can","family":"Aydogdu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bukavina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikmat A.","family":"Al-Ahmadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alhalabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lopez-Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Daniel","family":"Grass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Chatzkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea B.","family":"Apolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-7200","authenticated-orcid":false,"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.05.030_b0005","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.eururo.2025.04.008","article-title":"Clinical outcomes, genomic heterogeneity, and therapeutic considerations across histologic subtypes of urothelial carcinoma","volume":"88","author":"Chu","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0010","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.juro.2012.11.006","article-title":"Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis","volume":"189","author":"Linder","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0015","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male Genital organs-part B: prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0020","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.path.2022.07.003","article-title":"Urothelial carcinoma: divergent differentiation and morphologic subtypes","volume":"15","author":"Gandhi","year":"2022","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.eururo.2026.05.030_b0025","doi-asserted-by":"crossref","first-page":"695.e21","DOI":"10.1016\/j.urolonc.2025.07.024","article-title":"Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: a retrospective cohort study","volume":"43","author":"Bakaloudi","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0030","series-title":"EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS)","author":"Gontero","year":"2026"},{"key":"10.1016\/j.eururo.2026.05.030_b0035","unstructured":"European Association of Urology. EAU guidelines on muscle-invasive and metastatic bladder cancer. Arnhem, The Netherlands. http:\/\/uroweb.org\/guidelines\/compilations-of-all-guidelines\/."},{"key":"10.1016\/j.eururo.2026.05.030_b0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.urology.2007.03.033","article-title":"Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection","volume":"70","author":"Wasco","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2026.05.030_b0045","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438640","article-title":"Current advances in the management of nonurothelial subtypes of bladder cancer","volume":"44","author":"Vlachou","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.eururo.2026.05.030_b0050","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1002\/1097-0142(19811215)48:12<2643::AID-CNCR2820481216>3.0.CO;2-C","article-title":"The impact of schistosomiasis on the pathology of bladder carcinoma","volume":"48","author":"El-Bolkainy","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2026.05.030_b0055","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3390\/biomedicines13071548","article-title":"Detection of high-risk human Papillomavirus in bladder cancer: an exploratory study from a UK-based population","volume":"13","author":"Ahmed","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.eururo.2026.05.030_b0060","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1038\/s41467-022-34251-3","article-title":"FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation","volume":"13","author":"Warrick","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2026.05.030_b0065","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.eururo.2020.01.003","article-title":"Comprehensive assessment of immuno-oncology biomarkers in adenocarcinoma, urothelial carcinoma, and squamous-cell carcinoma of the bladder","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0070","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.urolonc.2015.06.006","article-title":"Molecular mechanisms of squamous differentiation in urothelial cell carcinoma: a paradigm for molecular subtyping of urothelial cell carcinoma of the bladder","volume":"33","author":"Adam","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0075","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.juro.2011.09.056","article-title":"Comparative outcomes of pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation in patients treated with radical cystectomy","volume":"187","author":"Ehdaie","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0080","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/cncr.22853","article-title":"Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of the University of Texas M D Anderson Cancer Center experience","volume":"110","author":"Kassouf","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2026.05.030_b0085","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1464-410X.2011.10357.x","article-title":"Survival after radical cystectomy of non-bilharzial squamous cell carcinoma vs urothelial carcinoma: a competing-risks analysis","volume":"109","author":"Abdollah","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.05.030_b0090","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s10147-019-01553-4","article-title":"A single-institute experience of trimodal bladder-preserving therapy for histologic variants of urothelial carcinoma","volume":"25","author":"Nagumo","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0095","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.eururo.2016.12.002","article-title":"Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy","volume":"72","author":"Krasnow","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0100","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.3390\/cancers14235766","article-title":"Differences in cancer-specific mortality after trimodal therapy for T2N0M0 bladder cancer according to histological subtype","volume":"14","author":"Barletta","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2026.05.030_b0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.clgc.2020.06.004","article-title":"Role of neoadjuvant chemotherapy in squamous variant histology in urothelial bladder cancer: does presence and percentage matter?","volume":"19","author":"Speir","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.05.030_b0110","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.urology.2006.10.029","article-title":"Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract","volume":"69","author":"Galsky","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2026.05.030_b0115","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/JU.0000000000000761","article-title":"Histological subtypes and response to PD-1\/PD-L1 blockade in advanced urothelial cancer: a retrospective study","volume":"204","author":"Miller","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102356","article-title":"Response and survival with immune checkpoint inhibitor in patients with advanced urothelial carcinoma and histology subtypes","volume":"23","author":"Bakaloudi","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.05.030_b0130","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1200\/JCO.20.01652","article-title":"Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors","volume":"38","author":"Apolo","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0135","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1200\/JCO.23.02233","article-title":"Final results from a Phase I trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced\/metastatic genitourinary tumors","volume":"42","author":"Apolo","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0140","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of Nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.eururo.2026.05.030_b0145","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.clgc.2023.05.014","article-title":"Metastatic bladder cancer expression and subcellular localization of Nectin-4 and Trop-2 in variant histology: A rapid autopsy study","volume":"21","author":"Ghali","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.05.030_b0150","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.05.030_b0155","doi-asserted-by":"crossref","unstructured":"Jindal T, Jiang CY, Alhalabi O, et al. Outcomes with enfortumab vedotin in patients with histologic subtypes of advanced urothelial carcinoma: analysis of the UNITE study. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2025.09.003.","DOI":"10.1016\/j.eururo.2025.09.003"},{"key":"10.1016\/j.eururo.2026.05.030_b0160","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/14796694.2025.2497719","article-title":"E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationale","volume":"21","author":"Chandran","year":"2025","journal-title":"Future Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0165","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1080\/14796694.2025.2516901","article-title":"A phase 2 study of sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors (SMART) - design and rationale","volume":"21","author":"Kydd","year":"2025","journal-title":"Future Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0170","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clgc.2020.07.011","article-title":"Bladder cancer: A comparison between non-urothelial variant histology and urothelial carcinoma across all stages and treatment modalities","volume":"19","author":"Deuker","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.05.030_b0175","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/his.13752","article-title":"Variants and new entities of bladder cancer","volume":"74","author":"Lopez-Beltran","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.eururo.2026.05.030_b0180","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1186\/s12885-023-11531-9","article-title":"Regular gastroscopy and colonoscopy during the evaluation of urachal cancer: do we really need them?","volume":"23","author":"Luo","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2026.05.030_b0185","article-title":"Clinical and genomic characterization of bladder carcinomas with glandular phenotype","volume":"6","author":"Almassi","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0190","article-title":"Urachal and Nonurachal adenocarcinomas of the urinary bladder: a comprehensive genomic profiling study","volume":"8","author":"Cigliola","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0195","doi-asserted-by":"crossref","first-page":"9041","DOI":"10.1002\/cam4.5639","article-title":"Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas","volume":"12","author":"Varadi","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.eururo.2026.05.030_b0200","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/s41379-021-00776-z","article-title":"Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications","volume":"34","author":"Cheng","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2026.05.030_b0205","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00345-018-2411-7","article-title":"Invasive non-urachal adenocarcinoma of the bladder: analysis of the National Cancer Database","volume":"37","author":"Davaro","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0210","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2024.42.4_suppl.630","article-title":"Clinical outcomes of frontline GemFLP in advanced urachal and non-urachal adenocarcinomas of the urinary tract: the MD Anderson Cancer Center (MDACC) experience","volume":"42","author":"Moussa","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0215","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/cam4.3699","article-title":"A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract","volume":"10","author":"Sarfaty","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.eururo.2026.05.030_b0220","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11912-022-01219-x","article-title":"Clinicopathological review of micropapillary urothelial carcinoma","volume":"24","author":"Kumar","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.eururo.2026.05.030_b0225","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3109\/00313025.2010.522173","article-title":"Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases","volume":"42","author":"Comp\u00e9rat","year":"2010","journal-title":"Pathology"},{"key":"10.1016\/j.eururo.2026.05.030_b0230","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.urolonc.2019.10.013","article-title":"Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma","volume":"38","author":"Yang","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0235","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2016.02.056","article-title":"Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer","volume":"70","author":"Guo","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0240","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41585-023-00847-7","article-title":"Molecular profile of bladder cancer progression to clinically aggressive subtypes","volume":"21","author":"Guo","year":"2024","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0245","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-13-1992","article-title":"A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma","volume":"20","author":"Ross","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2026.05.030_b0250","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/cncr.22756","article-title":"Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients","volume":"110","author":"Kamat","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2026.05.030_b0255","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.juro.2014.09.092","article-title":"Clinical outcomes of cT1 micropapillary bladder cancer","volume":"193","author":"Willis","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0260","doi-asserted-by":"crossref","first-page":"71.e1","DOI":"10.1016\/j.urolonc.2023.12.005","article-title":"Oncologic outcomes of intravesical therapy in the management of nonmuscle invasive bladder cancer with variant histology","volume":"42","author":"Lone","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0265","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.juro.2014.02.2565","article-title":"Clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder","volume":"192","author":"Spaliviero","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0270","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bju.13689","article-title":"Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer","volume":"119","author":"Fern\u00e1ndez","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.05.030_b0275","doi-asserted-by":"crossref","first-page":"E325","DOI":"10.1111\/j.1464-410X.2012.11751.x","article-title":"Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer","volume":"111","author":"Meeks","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.05.030_b0280","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1200\/JCO.2023.41.16_suppl.4592","article-title":"Survival outcomes of micropapillary versus classic variant, loco-regional bladder cancer: a 2004\u20132019 National Cancer Database analysis","volume":"41","author":"Garje","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0285","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.hoc.2014.10.011","article-title":"Nonurothelial bladder cancer and rare variant histologies","volume":"29","author":"Willis","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.eururo.2026.05.030_b0290","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/MOU.0000000000000089","article-title":"Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer","volume":"24","author":"Porten","year":"2014","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0295","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.urolonc.2014.01.020","article-title":"Micropapillary bladder cancer: current treatment patterns and review of the literature","volume":"32","author":"Willis","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0300","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.05.030_b0305","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1186\/s12885-025-14154-4","article-title":"RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: a multicenter, real-world, retrospective study","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2026.05.030_b0310","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1007\/s11255-025-04567-2","article-title":"A clinical study of RC48-ADC combined with PD-1 inhibitor in bladder preservation therapy for muscle-invasive bladder cancer (MIBC)-based on real-world data analysis","volume":"57","author":"Zhang","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2026.05.030_b0315","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.juro.2007.08.038","article-title":"Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder","volume":"178","author":"Wright","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0320","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1097\/00005392-199805000-00023","article-title":"Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases","volume":"159","author":"Lopez-Beltran","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0325","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.celrep.2019.04.048","article-title":"Dysregulation of EMT drives the progression to clinically aggressive sarcomatoid bladder cancer","volume":"27","author":"Guo","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.eururo.2026.05.030_b0330","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.urolonc.2016.12.006","article-title":"Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy","volume":"35","author":"Moschini","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0335","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrurol.2017.125","article-title":"Characteristics and clinical significance of histological variants of bladder cancer","volume":"14","author":"Moschini","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0340","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2026.05.030_b0345","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00345-016-1962-8","article-title":"Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer","volume":"35","author":"Sui","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0350","doi-asserted-by":"crossref","first-page":"507.e1","DOI":"10.1016\/j.clgc.2023.03.015","article-title":"Sarcomatoid urothelial carcinoma is associated with limited response to neoadjuvant chemotherapy and poor oncologic outcomes after radical cystectomy","volume":"21","author":"Sekar","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.05.030_b0355","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/bju.15428","article-title":"Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy","volume":"129","author":"Almassi","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.05.030_b0360","doi-asserted-by":"crossref","first-page":"S1201","DOI":"10.1016\/j.annonc.2023.09.1012","article-title":"2363MO A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2)","volume":"34","author":"Szabados","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0365","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ng.3503","article-title":"Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer","volume":"48","author":"Al-Ahmadie","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2026.05.030_b0370","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41416-020-01244-2","article-title":"Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma","volume":"124","author":"Teo","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2026.05.030_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.105788","article-title":"Plasmacytoid urothelial carcinoma of the urinary bladder: A single institution experience with focus on next-generation sequencing (NGS) and PD-L1 immunohistochemistry","volume":"158","author":"Korentzelos","year":"2025","journal-title":"Hum Pathol"},{"key":"10.1016\/j.eururo.2026.05.030_b0380","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.euf.2017.06.013","article-title":"The impact of plasmacytoid variant histology on the survival of patients with urothelial carcinoma of bladder after radical cystectomy","volume":"5","author":"Li","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.05.030_b0385","doi-asserted-by":"crossref","first-page":"389.e7","DOI":"10.1016\/j.urolonc.2023.02.003","article-title":"Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma","volume":"41","author":"Davaro","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102100","article-title":"Adjuvant chemotherapy and survival after radical cystectomy in histologic subtype bladder cancer","volume":"22","author":"Koehne","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.05.030_b0395","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/JU.0000000000003778","article-title":"Long-term oncological outcomes in patients diagnosed with nonmetastatic plasmacytoid variant of bladder cancer: a 20-year University of Texas MD Anderson Cancer Center experience","volume":"211","author":"Sood","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0400","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3233\/BLC-190258","article-title":"Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes","volume":"6","author":"Diamantopoulos","year":"2020","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2026.05.030_b0405","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.eururo.2025.07.002","article-title":"Neoadjuvant pembrolizumab and accelerated methotrexate, vinblastine, doxorubicin, and cisplatin in nonurothelial histologic subtypes of muscle-invasive bladder cancer: a Phase 2 trial","volume":"88","author":"Raychaudhuri","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0410","doi-asserted-by":"crossref","DOI":"10.1177\/2632010X241276943","article-title":"Clinical and pathological features of the nested subtype of urothelial carcinoma with lymph node metastasis as the initial presentation: a case report","volume":"17","author":"Li","year":"2024","journal-title":"Clin Pathol"},{"key":"10.1016\/j.eururo.2026.05.030_b0415","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.humpath.2009.07.015","article-title":"Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 30 pure and mixed cases","volume":"41","author":"Wasco","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.eururo.2026.05.030_b0420","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3390\/cancers12030763","article-title":"Pure large nested variant of urothelial carcinoma (LNUC) is the prototype of an FGFR3 mutated aggressive urothelial carcinoma with luminal-papillary phenotype","volume":"12","author":"Weyerer","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2026.05.030_b0425","article-title":"Non-urothelial and urothelial variants of bladder cancer","volume":"33","author":"Yu","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.eururo.2026.05.030_b0430","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00428-014-1601-y","article-title":"Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder","volume":"465","author":"Beltran","year":"2014","journal-title":"Virchows Arch"},{"key":"10.1016\/j.eururo.2026.05.030_b0435","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jamaoncol.2024.3900","article-title":"Rogaratinib plus atezolizumab in cisplatin-ineligible patients with FGFR RNA-overexpressing urothelial cancer: the FORT-2 Phase 1b nonrandomized clinical trial","volume":"10","author":"Sweis","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0440","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male Genital organs-part B: prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0445","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2559.2004.01980.x","article-title":"Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases","volume":"46","author":"Abrahams","year":"2005","journal-title":"Histopathology"},{"key":"10.1016\/j.eururo.2026.05.030_b0450","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70594","article-title":"Histopathologic progression and metastatic relapse outcomes in small cell neuroendocrine carcinomas of the urinary tract","volume":"14","author":"Moussa","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.eururo.2026.05.030_b0455","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0002-9440(10)62369-3","article-title":"Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma","volume":"166","author":"Cheng","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eururo.2026.05.030_b0460","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-17-2655","article-title":"Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis","volume":"24","author":"Chang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2026.05.030_b0465","doi-asserted-by":"crossref","first-page":"8402","DOI":"10.1073\/pnas.0600906103","article-title":"The RNA-binding protein Musashi is required intrinsically to maintain stem cell identity","volume":"103","author":"Siddall","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2026.05.030_b0470","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2016.12.005","article-title":"MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition","volume":"31","author":"Mollaoglu","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2026.05.030_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101201","article-title":"Urothelial-to-neural plasticity drives progression to small cell bladder cancer","volume":"23","author":"Yang","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.eururo.2026.05.030_b0480","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2019.37.7_suppl.486","article-title":"Prophylactic cranial irradiation (PCI) significantly decreases risk of brain metastases in patients with bulky, higher stage small-cell urothelial cancer","volume":"37","author":"Choi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0485","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.eururo.2012.04.020","article-title":"Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center","volume":"64","author":"Lynch","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0490","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1002\/cncr.30907","article-title":"Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology","volume":"123","author":"Vetterlein","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2026.05.030_b0495","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.2008.19.0256","article-title":"Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide\/doxorubicin and etoposide\/cisplatin in small-cell urothelial cancer","volume":"27","author":"Siefker-Radtke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103964","article-title":"Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder","volume":"9","author":"Myers","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.eururo.2026.05.030_b0505","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.ju.0000162085.20043.1f","article-title":"Radical cystectomy for primary neuroendocrine tumors of the bladder: the University of Southern California experience","volume":"174","author":"Quek","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0510","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/01.ju.0000132413.85866.fc","article-title":"Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience","volume":"172","author":"Siefker-Radtke","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.05.030_b0515","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.ijrobp.2021.02.003","article-title":"Treatment outcomes for small cell carcinoma of the bladder: results from a UK patient retrospective cohort study","volume":"110","author":"Chau","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2026.05.030_b0520","first-page":"55","article-title":"Small cell carcinoma of the bladder: A population-based analysis of long-term outcomes after radical cystectomy and bladder conservation with chemoradiotherapy","volume":"16","author":"Oh","year":"2022","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2026.05.030_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102208","article-title":"Small cell bladder cancer: treatment patterns for local disease and associated outcomes. A retrospective cohort study","volume":"22","author":"Bakaloudi","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.05.030_b0530","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.euf.2017.09.001","article-title":"Treatment patterns and survival outcomes for patients with small cell carcinoma of the bladder","volume":"4","author":"Fischer-Valuck","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.05.030_b0535","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.33328","article-title":"Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies","volume":"127","author":"McGregor","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2026.05.030_b0540","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.3390\/curroncol31060254","article-title":"Durable objective response to lurbinectedin in small cell bladder cancer with TP53 mutation: A molecular-directed strategy","volume":"31","author":"Moussa","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0545","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1080\/14796694.2025.2480534","article-title":"A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)-design and rationale","volume":"21","author":"Simon","year":"2025","journal-title":"Future Oncol"},{"key":"10.1016\/j.eururo.2026.05.030_b0550","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/1078-0432.CCR-18-1278","article-title":"Transcriptomic and protein analysis of small-cell bladder cancer (SCBC) identifies prognostic biomarkers and DLL3 as a relevant therapeutic target","volume":"25","author":"Koshkin","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826022098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826022098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:33:14Z","timestamp":1791837194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826022098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0302283826022098"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.05.030","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}